Satoshi Katagiri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Satoshi Katagiri has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Masakazu Yamamoto
Institute of Gastroenterology, Tokyo Women’s Medical University
23 shared publications - Ken Takasaki
Tokyo Women’s Medical University
14 shared publications Takehito Ohtsubo
8 shared publications- Takehito Otsubo
Department of Gastroenterological and General Surgery, St. Marianna University School of Medicine, Kawasaki, Japan
8 shared publications Hideo Katsuragawa
7 shared publicationsShunichi Ariizumi
Department of Surgery, Institute of Gastroenterology, Tokyo Women’s Medical University
6 shared publications
Latest Publications
- 1 June 2018
- Published by The Japanese Journal of Gastroenterological Surgery in The Japanese Journal of Gastroenterological Surgery
- Vol. 51 (6) , 415-422
An HNF1α-Inactivated Hepatocellular Adenoma
症例は33歳の男性で,既往歴はなく,肝炎ウイルスマーカーは陰性であった.人間ドックのPETにて肝S4に高度集積(SUV max of 10.4)を認めた.血液生化学検査では,異常値は認めなかった.USでは,肝S4に径4 cm,境界が明瞭な淡いhyperechoic lesionを認めた.単純CTでは低吸収であり,動脈相で等吸収,門脈相で低吸収,遅延相で低吸収であった.EOB-MRIでは,肝細胞造影相で境界明瞭な低信号,T1脂肪抑制で低信号であり脂肪成分を含む腫瘍が考えられた.初回診断時より5か月後,悪性腫瘍が否定できないため,肝部分切除を施行した.肉眼所見では,割面は弾性軟で,黄色を呈した充実性の境界明瞭な腫瘍であった.病理診断は肝細胞腺腫(hepatocellular adenoma;以下,HCAと略記)で,免疫組織学的にHNF1α不活化型と診断した.PETで高集積となるHCAは,極めてまれであるので報告する.
- 1 June 2018
- Published by The Japanese Journal of Gastroenterological Surgery in The Japanese Journal of Gastroenterological Surgery
- Vol. 51 (6) , 415-422
An HNF1α-Inactivated Hepatocellular Adenoma
症例は33歳の男性で,既往歴はなく,肝炎ウイルスマーカーは陰性であった.人間ドックのPETにて肝S4に高度集積(SUV max of 10.4)を認めた.血液生化学検査では,異常値は認めなかった.USでは,肝S4に径4 cm,境界が明瞭な淡いhyperechoic lesionを認めた.単純CTでは低吸収であり,動脈相で等吸収,門脈相で低吸収,遅延相で低吸収であった.EOB-MRIでは,肝細胞造影相で境界明瞭な低信号,T1脂肪抑制で低信号であり脂肪成分を含む腫瘍が考えられた.初回診断時より5か月後,悪性腫瘍が否定できないため,肝部分切除を施行した.肉眼所見では,割面は弾性軟で,黄色を呈した充実性の境界明瞭な腫瘍であった.病理診断は肝細胞腺腫(hepatocellular adenoma;以下,HCAと略記)で,免疫組織学的にHNF1α不活化型と診断した.PETで高集積となるHCAは,極めてまれであるので報告する.
- 1 October 2015
- Vol. 42 (10) , 1164-8
[I. Repeat hepatectomy for recurrent hepatocellular carcinoma--review of literature].
- 1 October 2015
- Vol. 42 (10) , 1164-8
[I. Repeat hepatectomy for recurrent hepatocellular carcinoma--review of literature].
- 24 February 2015
- Vol. 61 (136) , 2345-8
Anatomic variations of hepatic artery and new clinical classification based on abdominal angiographic images of 1200 cases.
There is wide variation in the branches of the hepatic artery. We aimed to classify these variations clinically on the basis of abdominal angiographic images in order to find out the suitable classification. Anatomic variations of the hepatic artery of 1200 patients were analyzed at Tokyo Women's Medical University from 2000 to 2010, and Classified into four categories: "Y", "I-I", "Y plus I", and "I-I plus I". Patients with a proper hepatic artery were categorized as "Y", and those without as "I-I", to describe the arteries morphologically. We denoted an accessory artery as "I", and described it as being to the left or right of "Y"; i.e., "I, Y" or "Y, I", respectively. Normal hepatic anatomy was observed in 77.2% (926 subjects), and variations were found in 22.8% (274 subjects). Of all the patients, 3.8% (45 subjects) could not be classified using Michels' classification. On the other hand, when variations were classified using our classification, all variations could be classified into either Category Y (85.6%, 1027 subjects) or Category I-I (14.4%, 173 subjects). Our simplified new clinical classification of hepatic artery variants would be useful for preoperative planning in hepato-biliary-pancreatic surgery and liver transplantation.
- 24 February 2015
- Vol. 61 (136) , 2345-8
Anatomic variations of hepatic artery and new clinical classification based on abdominal angiographic images of 1200 cases.
There is wide variation in the branches of the hepatic artery. We aimed to classify these variations clinically on the basis of abdominal angiographic images in order to find out the suitable classification. Anatomic variations of the hepatic artery of 1200 patients were analyzed at Tokyo Women's Medical University from 2000 to 2010, and Classified into four categories: "Y", "I-I", "Y plus I", and "I-I plus I". Patients with a proper hepatic artery were categorized as "Y", and those without as "I-I", to describe the arteries morphologically. We denoted an accessory artery as "I", and described it as being to the left or right of "Y"; i.e., "I, Y" or "Y, I", respectively. Normal hepatic anatomy was observed in 77.2% (926 subjects), and variations were found in 22.8% (274 subjects). Of all the patients, 3.8% (45 subjects) could not be classified using Michels' classification. On the other hand, when variations were classified using our classification, all variations could be classified into either Category Y (85.6%, 1027 subjects) or Category I-I (14.4%, 173 subjects). Our simplified new clinical classification of hepatic artery variants would be useful for preoperative planning in hepato-biliary-pancreatic surgery and liver transplantation.
- 1 April 2014
- Vol. 111 (4) , 787-96
[Multiple large hepatocellular adenomas in a patient with glycogen storage disease type Ia].
A man diagnosed at birth with glycogen storage disease type Ia was found to have multiple hepatocellular adenomas at 15 years of age. At 18 years of age, he underwent transarterial tumor embolization in segments 4 and 5. At 27 years of age, the tumor in segment 4 had increased in size on follow-up computed tomography, and he was referred to our hospital. Because the tumor was large, increasing in size, and we could not exclude malignancy, we performed resection of segments 4 and 8 of the liver and partial resection of segment 5 for excisional biopsy. The pathological diagnosis was multiple inflammatory hepatocellular adenomas.
- 1 April 2014
- Vol. 111 (4) , 787-96
[Multiple large hepatocellular adenomas in a patient with glycogen storage disease type Ia].
A man diagnosed at birth with glycogen storage disease type Ia was found to have multiple hepatocellular adenomas at 15 years of age. At 18 years of age, he underwent transarterial tumor embolization in segments 4 and 5. At 27 years of age, the tumor in segment 4 had increased in size on follow-up computed tomography, and he was referred to our hospital. Because the tumor was large, increasing in size, and we could not exclude malignancy, we performed resection of segments 4 and 8 of the liver and partial resection of segment 5 for excisional biopsy. The pathological diagnosis was multiple inflammatory hepatocellular adenomas.
- Open Access
- 13 January 2014
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 10 (4) , 970-976
Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma
The recurrence rate after surgery in patients with hepatocellular carcinoma (HCC) is very high, while prognosis is quite poor. However, there is no standard treatment to prevent recurrence of HCC after a curative operation. In this study, we investigated the clinical utilization of an autologous tumor lysate-pulsed dendritic cell vaccine plus ex vivo activated T cell transfer (ATVAC) in an adjuvant setting for postoperative HCC as a non-randomized controlled trial. Ninety-four patients with invasive HCC received informed consent information regarding the study, and 42 opted to have the ATVAC after surgery. Their recurrence-free survival (RFS) and overall survival (OS) were measured after 5 years and compared with those of 52 patients who selected to have the curative operation alone. The median RFS and OS were 24.5 months and 97.7 months in the patients receiving adjuvant ATVAC and 12.6 months and 41.0 months in the group receiving surgery alone (P = 0.011 and 0.029). In the treated group, patients with positive delayed-type hypersensitivity (DTH) had a better prognosis (RFS P = 0.019, OS P = 0.025). No adverse events of grade 3 or more were observed. A postoperative dendritic cell vaccine plus activated T cell transfer would be a feasible and effective treatment for preventing recurrence in HCC patients and achieving long-term survival especially in DTH positive patients.
- 13 January 2014
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 10 (4) , 970-976
Open AccessPostoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma
The recurrence rate after surgery in patients with hepatocellular carcinoma (HCC) is very high, while prognosis is quite poor. However, there is no standard treatment to prevent recurrence of HCC after a curative operation. In this study, we investigated the clinical utilization of an autologous tumor lysate-pulsed dendritic cell vaccine plus ex vivo activated T cell transfer (ATVAC) in an adjuvant setting for postoperative HCC as a non-randomized controlled trial. Ninety-four patients with invasive HCC received informed consent information regarding the study, and 42 opted to have the ATVAC after surgery. Their recurrence-free survival (RFS) and overall survival (OS) were measured after 5 years and compared with those of 52 patients who selected to have the curative operation alone. The median RFS and OS were 24.5 months and 97.7 months in the patients receiving adjuvant ATVAC and 12.6 months and 41.0 months in the group receiving surgery alone (P = 0.011 and 0.029). In the treated group, patients with positive delayed-type hypersensitivity (DTH) had a better prognosis (RFS P = 0.019, OS P = 0.025). No adverse events of grade 3 or more were observed. A postoperative dendritic cell vaccine plus activated T cell transfer would be a feasible and effective treatment for preventing recurrence in HCC patients and achieving long-term survival especially in DTH positive patients.
- Open Access
- 17 April 2013
- Published by Springer Nature in Surgery Today
- Vol. 44 (2) , 219-226
Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus
In recent years, various treatment options have become available for patients with hepatocellular carcinoma (HCC) according to the degree of background liver damage, tumor diameter and other factors associated with disease progression. Therapy has also shifted toward evidence-based treatment. Policies for the management of HCC with portal vein tumor thrombus, which has been considered an intractable condition, have not been established. Surgical resection was previously positioned as the treatment of choice, but the outcomes after resection alone were found to be disappointing. At present, multiple interdisciplinary treatments, combining resection with intra-arterial chemotherapy, radiotherapy, systemic chemotherapy and/or immunotherapy, are used on a trial-and-error basis since no standard regimens have been developed. Clinical trials of surgery combined with transarterial chemoembolization, hepatic arterial infusion of chemotherapy and radiation have obtained improved 5-year survival rates of 21.5–56 %. The safety of surgical resection in HCC with major portal vein tumor thrombus has improved, but the optimal type(s) and timing of auxiliary therapy to use in combination with resection remain to be defined.
- 17 April 2013
- Published by Springer Nature in Surgery Today
- Vol. 44 (2) , 219-226
Open AccessMultidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus
In recent years, various treatment options have become available for patients with hepatocellular carcinoma (HCC) according to the degree of background liver damage, tumor diameter and other factors associated with disease progression. Therapy has also shifted toward evidence-based treatment. Policies for the management of HCC with portal vein tumor thrombus, which has been considered an intractable condition, have not been established. Surgical resection was previously positioned as the treatment of choice, but the outcomes after resection alone were found to be disappointing. At present, multiple interdisciplinary treatments, combining resection with intra-arterial chemotherapy, radiotherapy, systemic chemotherapy and/or immunotherapy, are used on a trial-and-error basis since no standard regimens have been developed. Clinical trials of surgery combined with transarterial chemoembolization, hepatic arterial infusion of chemotherapy and radiation have obtained improved 5-year survival rates of 21.5–56 %. The safety of surgical resection in HCC with major portal vein tumor thrombus has improved, but the optimal type(s) and timing of auxiliary therapy to use in combination with resection remain to be defined.
- 1 November 2012
- Vol. 39 (12) , 1843-5
[Examination of the effect of anesthesia on radiofrequency ablation of hepatocellular carcinoma-a patient survey on anesthesia for radiofrequency ablation].
Radiofrequency ablation(RFA) is minimally invasive and is easy to perform. In the RFA procedure, puncture and passing of the electrical current are painful. Therefore, some facilities use general anesthesia for RFA. In order to evaluate the use of general anesthesia for RFA of hepatocellular carcinoma, a questionnaire survey was conducted. With the cooperation of Tokyo liver-tomo-no-kai(Tokyo Liver Association), a questionnaire survey was conducted for patients who underwent RFA. In the survey, data on the following were obtained "type of anesthesia used", "number of RFA treatment points", "duration of treatment", "length of impact of pain", and "if you need to receive RFA treatment again, how would you feel about this." The ratio of local anesthesia (LA) to general anesthesia (GA) was 113:24. The ratios of the numbers of patients who felt pain to those who felt no pain were 64:49 (LA) and 0:24 (GA). The ratios of the patients who wished to not receive RFA again to the patients who were comfortable with receiving RFA were 65:45 (LA) and 4:20 (GA). GA achieves better pain control compared to LA, and the patients who receive GA have greater tolerance of RFA.
- 1 November 2012
- Vol. 39 (12) , 1843-5
[Examination of the effect of anesthesia on radiofrequency ablation of hepatocellular carcinoma-a patient survey on anesthesia for radiofrequency ablation].
Radiofrequency ablation(RFA) is minimally invasive and is easy to perform. In the RFA procedure, puncture and passing of the electrical current are painful. Therefore, some facilities use general anesthesia for RFA. In order to evaluate the use of general anesthesia for RFA of hepatocellular carcinoma, a questionnaire survey was conducted. With the cooperation of Tokyo liver-tomo-no-kai(Tokyo Liver Association), a questionnaire survey was conducted for patients who underwent RFA. In the survey, data on the following were obtained "type of anesthesia used", "number of RFA treatment points", "duration of treatment", "length of impact of pain", and "if you need to receive RFA treatment again, how would you feel about this." The ratio of local anesthesia (LA) to general anesthesia (GA) was 113:24. The ratios of the numbers of patients who felt pain to those who felt no pain were 64:49 (LA) and 0:24 (GA). The ratios of the patients who wished to not receive RFA again to the patients who were comfortable with receiving RFA were 65:45 (LA) and 4:20 (GA). GA achieves better pain control compared to LA, and the patients who receive GA have greater tolerance of RFA.
- 1 September 2011
- Vol. 108 (9) , 1540-5
[Ileocecal resection for idiopathic intussusception in an adult].
A 60-year-old woman presented with abdominal pain and bloody stools. On examination, there was muscular guarding and rebound tenderness in the right abdomen. Abdominal ultrasonography and CT showed a concentric structure in the ascending colon and ascites. Emergency surgery was performed with a preoperative diagnosis of idiopathic intussusception. At operation, an intussusception was not seen, but ileocecal resection was performed to remove a possible tumor. No lesion that could have caused intussusception was identified in the resected bowel segment, so the condition was idiopathic.
- 1 September 2011
- Vol. 108 (9) , 1540-5
[Ileocecal resection for idiopathic intussusception in an adult].
A 60-year-old woman presented with abdominal pain and bloody stools. On examination, there was muscular guarding and rebound tenderness in the right abdomen. Abdominal ultrasonography and CT showed a concentric structure in the ascending colon and ascites. Emergency surgery was performed with a preoperative diagnosis of idiopathic intussusception. At operation, an intussusception was not seen, but ileocecal resection was performed to remove a possible tumor. No lesion that could have caused intussusception was identified in the resected bowel segment, so the condition was idiopathic.
- 11 July 2008
- Vol. 55, 531-4
Therapeutic effect of TAE can be predicted by abdominal-enhanced CT findings in HCC.
In order to improve the therapeutic efficacy of transcatheter arterial embolization (TAE) in hepatocellular carcinoma (HCC), the relationship between CT findings and antitumor efficacy was studied. The therapeutic effect on CT 1 year after TAE was respectively studied for 100 nodules of HCC where TAE was performed. The pre-treatment abdominal CT findings were classified, and the therapeutic effect was compared with regard to these attributes. Tumors determined to have no recurrence at the treated site (defined as "complete necrosis") accounted for 58% overall. The percentage of "complete necrosis" in pre-TAE CT findings by type showed that 1) in terms of tumor shape, 73.4% were smooth type, 34.5% irregular type, and 0% invasive type (p = 0.0003), 2) in terms of the presence of corona nodules, nodules where "complete necrosis" was achieved were corona-positive in 67.7% and coronanegative in 37.1% (p = 0.003), 3) in terms of tumor size, 68.3% of tumors were smaller than 3.0cm and 28.6% were larger than 3.1cm, 4) in terms of location, 64.6% of tumors were in a peripheral location and 28.6% in a central location (p = 0.006). The therapeutic effect of TAE is improved by adequate diagnosis of the tumor characteristics found on pre-treatment CT.
- 11 July 2008
- Vol. 55, 531-4
Therapeutic effect of TAE can be predicted by abdominal-enhanced CT findings in HCC.
In order to improve the therapeutic efficacy of transcatheter arterial embolization (TAE) in hepatocellular carcinoma (HCC), the relationship between CT findings and antitumor efficacy was studied. The therapeutic effect on CT 1 year after TAE was respectively studied for 100 nodules of HCC where TAE was performed. The pre-treatment abdominal CT findings were classified, and the therapeutic effect was compared with regard to these attributes. Tumors determined to have no recurrence at the treated site (defined as "complete necrosis") accounted for 58% overall. The percentage of "complete necrosis" in pre-TAE CT findings by type showed that 1) in terms of tumor shape, 73.4% were smooth type, 34.5% irregular type, and 0% invasive type (p = 0.0003), 2) in terms of the presence of corona nodules, nodules where "complete necrosis" was achieved were corona-positive in 67.7% and coronanegative in 37.1% (p = 0.003), 3) in terms of tumor size, 68.3% of tumors were smaller than 3.0cm and 28.6% were larger than 3.1cm, 4) in terms of location, 64.6% of tumors were in a peripheral location and 28.6% in a central location (p = 0.006). The therapeutic effect of TAE is improved by adequate diagnosis of the tumor characteristics found on pre-treatment CT.
- 1 June 2008
- Vol. 105 (6) , 795-801
[Postoperative interferon therapy after resection of hepatitis C virus-related hepatocellular carcinoma].
- 1 June 2008
- Vol. 105 (6) , 795-801
[Postoperative interferon therapy after resection of hepatitis C virus-related hepatocellular carcinoma].